The Asia Pacific pulmonary drug delivery market is anticipated to grow with a CAGR of 6.50%, during the forecast period of 2019 to 2028. The high prevalence of chronic obstructive pulmonary disease (COPD) and the increasing number of asthmatic and allergic rhinitis patients are attributed to the region’s market growth. The Asia Pacific pulmonary drug delivery market growth is assessed across India, Japan, Vietnam, China, Thailand, South Korea, Australia & New Zealand, Indonesia, and the rest of the Asia Pacific.
ASIA PACIFIC PULMONARY DRUG DELIVERY MARKET FORECAST 2019-2028
Asia Pacific Pulmonary Drug Delivery Market by Application (Asthma, Chronic Obstructive Pulmonary Disease, Allergic Rhinitis, Cystic Fibrosis, Other Applications) by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-commerce) by End-user (Hospitals & Clinics, Homecare) by Product (Metered Dose Inhalers, Dry Powder Inhalers, Nebulizer (Pneumatic Nebulizer (Breath Actuated Pneumatic Nebulizer, Vented Pneumatic Nebulizer), Mesh Nebulizer (Vibrating Mesh Nebulizer, Static Mesh Nebulizer), Ultrasonic Nebulizer), Accessories) and by Geography.
The Asia Pacific pulmonary drug delivery market is anticipated to grow with a CAGR of 6.50%, during the forecast period of 2019 to 2028. The high prevalence of chronic obstructive pulmonary disease (COPD) and the increasing number of asthmatic and allergic rhinitis patients are attributed to the region’s market growth.
To know more about this report, request a free sample copy
The Asia Pacific pulmonary drug delivery market growth is assessed across India, Japan, Vietnam, China, Thailand, South Korea, Australia & New Zealand, Indonesia, and the rest of the Asia Pacific. According to the study conducted by Tulane University in 2018, chronic obstructive pulmonary disease (COPD) is highly prevalent across China, with more than 8% of the nation’s adult population suffering from it. The severity of the chronic disorder and its mortality rate is projected to exponentially rise in the upcoming years, owing to the growing geriatric population and the constant increase in smoking rates, primarily among women.
Moreover, the presence of organizations like Project HOPE and its alliance with industry pioneers to establish the China Alliance of Respiratory Diseases Prevention and Treatment (CARD) program is predicted to fuel the market growth. This collaboration is likely to improve the lives of people impacted by respiratory diseases, as well. Additionally, economic developments and the rise in disposable income are expected to make China one of the largest-revenue generating markets for pulmonary drug delivery.
Agilent Technologies Inc, headquartered in the United States, provides software services, instruments, and consumable solutions to identify, quantify, and analyze the physical and biological properties of products as well as substances. The enterprise operates R&D centers and manufacturing facilities in the Asia Pacific, Europe, and North America. Moreover, in May 2020, the company announced the Food and Drug Administration (FDA) approval for its product, PD-L1 IHC 28-8 pharmDx.
To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.
- RESEARCH SCOPE & METHODOLOGY
- STUDY OBJECTIVES
- SCOPE OF STUDY
- METHODOLOGY
- ASSUMPTIONS & LIMITATIONS
- EXECUTIVE SUMMARY
- MARKET SIZE & ESTIMATES
- MARKET OVERVIEW
- MARKET DYNAMICS
- PARENT MARKET ANALYSIS: DRUG DELIVERY MARKET
- DEVELOPMENT OF DRUG DELIVERY SYSTEM
- MARKET DEFINITION
- KEY DRIVERS
- GROWING PREVALENCE OF RESPIRATORY DISEASE
- ADVANCEMENTS IN TECHNOLOGY
- RISING GERIATRIC POPULATION
- KEY RESTRAINTS
- STRINGENT REGULATION AND PATENT EXPIRY
- INCREASING DRUG RECALLS AND DRUG FAILURES
- SIDE EFFECTS AND RISK ASSOCIATED WITH THE DRUGS
- KEY ANALYTICS
- PORTER’S FIVE FORCE ANALYSIS
- THREAT OF NEW ENTRY
- THREAT OF SUBSTITUTION
- BUYER’S POWER
- SUPPLIER’S POWER
- COMPETITIVE RIVALRY
- REGULATORY FRAMEWORK
- IMPACT OF COVID-19 ON PULMONARY DRUG DELIVERY MARKET
- OPPORTUNITY MATRIX
- VENDOR LANDSCAPE
- KEY INVESTMENT INSIGHTS
- PORTER’S FIVE FORCE ANALYSIS
- MARKET BY APPLICATION
- ASTHMA
- CHRONIC OBSTRUCTIVE PULMONARY DISEASE
- ALLERGIC RHINITIS
- CYSTIC FIBROSIS
- OTHER APPLICATIONS
- MARKET BY DISTRIBUTION CHANNEL
- HOSPITAL PHARMACIES
- RETAIL PHARMACIES
- E-COMMERCE
- MARKET BY END-USER
- HOSPITALS & CLINICS
- HOMECARE
- MARKET BY PRODUCT
- METERED DOSE INHALERS
- DRY POWDER INHALERS
- NEBULIZER
- PNEUMATIC NEBULIZER
- MESH NEBULIZER
- ULTRASONIC NEBULIZER
- ACCESSORIES
- GEOGRAPHICAL ANALYSIS
- ASIA PACIFIC
- CHINA
- JAPAN
- INDIA
- AUSTRALIA & NEW ZEALAND
- SOUTH KOREA
- THAILAND
- INDONESIA
- VIETNAM
- REST OF ASIA PACIFIC
- ASIA PACIFIC
- COMPANY PROFILES
- 3M COMPANY
- ACTELION PHARMACEUTICALS LTD
- AEROGEN
- AGILENT TECHNOLOGIES INC
- ASTRAZENECA PLC
- BOEHRINGER INGELHEIM GMBH
- CLEMENT CLARKE INTERNATIONAL
- GF HEALTH PRODUCTS INC
- GLAXOSMITHKLINE PLC
- KONINKLIJKE PHILIPS NV
- MERCK & CO INC
- NOVARTIS AG
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED
- VECTURA GROUP PLC
TABLE LIST
TABLE 1: MARKET SNAPSHOT – PULMONARY DRUG DELIVERY
TABLE 2: ASIA PACIFIC PULMONARY DRUG DELIVERY MARKET, BY APPLICATION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 3: ASIA PACIFIC PULMONARY DRUG DELIVERY MARKET, BY APPLICATION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 4: ASIA PACIFIC PULMONARY DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 5: ASIA PACIFIC PULMONARY DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 6: ASIA PACIFIC PULMONARY DRUG DELIVERY MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 7: ASIA PACIFIC PULMONARY DRUG DELIVERY MARKET, BY END-USER, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 8: ASIA PACIFIC PULMONARY DRUG DELIVERY MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 9: ASIA PACIFIC PULMONARY DRUG DELIVERY MARKET, BY PRODUCT, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 10: ASIA PACIFIC NEBULIZER MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 11: ASIA PACIFIC NEBULIZER MARKET, BY TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 12: ASIA PACIFIC PULMONARY DRUG DELIVERY MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 13: ASIA PACIFIC PULMONARY DRUG DELIVERY MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
FIGURES LIST
FIGURE 1: PORTER’S FIVE FORCE ANALYSIS
FIGURE 2: OPPORTUNITY MATRIX
FIGURE 3: VENDOR LANDSCAPE
FIGURE 4: KEY INVESTMENT INSIGHTS
FIGURE 5: ASIA PACIFIC PULMONARY DRUG DELIVERY MARKET, BY APPLICATION, IN 2019
FIGURE 6: ASIA PACIFIC PULMONARY DRUG DELIVERY MARKET, BY ASTHMA, 2019-2028 (IN $ MILLION)
FIGURE 7: ASIA PACIFIC PULMONARY DRUG DELIVERY MARKET, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2019-2028 (IN $ MILLION)
FIGURE 8: ASIA PACIFIC PULMONARY DRUG DELIVERY MARKET, BY ALLERGIC RHINITIS, 2019-2028 (IN $ MILLION)
FIGURE 9: ASIA PACIFIC PULMONARY DRUG DELIVERY MARKET, BY CYSTIC FIBROSIS, 2019-2028 (IN $ MILLION)
FIGURE 10: ASIA PACIFIC PULMONARY DRUG DELIVERY MARKET, BY OTHER APPLICATIONS, 2019-2028 (IN $ MILLION)
FIGURE 11: ASIA PACIFIC PULMONARY DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, IN 2019
FIGURE 12: ASIA PACIFIC PULMONARY DRUG DELIVERY MARKET, BY HOSPITAL PHARMACIES, 2019-2028 (IN $ MILLION)
FIGURE 13: ASIA PACIFIC PULMONARY DRUG DELIVERY MARKET, BY RETAIL PHARMACIES, 2019-2028 (IN $ MILLION)
FIGURE 14: ASIA PACIFIC PULMONARY DRUG DELIVERY MARKET, BY E-COMMERCE, 2019-2028 (IN $ MILLION)
FIGURE 15: ASIA PACIFIC PULMONARY DRUG DELIVERY MARKET, BY END-USER, IN 2019
FIGURE 16: ASIA PACIFIC PULMONARY DRUG DELIVERY MARKET, BY HOSPITALS & CLINICS, 2019-2028 (IN $ MILLION)
FIGURE 17: ASIA PACIFIC PULMONARY DRUG DELIVERY MARKET, BY HOMECARE, 2019-2028 (IN $ MILLION)
FIGURE 18: ASIA PACIFIC PULMONARY DRUG DELIVERY MARKET, BY PRODUCT, IN 2019
FIGURE 19: ASIA PACIFIC PULMONARY DRUG DELIVERY MARKET, BY METERED DOSE INHALERS, 2019-2028 (IN $ MILLION)
FIGURE 20: ASIA PACIFIC PULMONARY DRUG DELIVERY MARKET, BY DRY POWDER INHALERS, 2019-2028 (IN $ MILLION)
FIGURE 21: ASIA PACIFIC PULMONARY DRUG DELIVERY MARKET, BY NEBULIZER, 2019-2028 (IN $ MILLION)
FIGURE 22: ASIA PACIFIC NEBULIZER MARKET, BY PNEUMATIC NEBULIZER, 2019-2028 (IN $ MILLION)
FIGURE 23: ASIA PACIFIC NEBULIZER MARKET, BY MESH NEBULIZER, 2019-2028 (IN $ MILLION)
FIGURE 24: ASIA PACIFIC NEBULIZER MARKET, BY ULTRASONIC NEBULIZER, 2019-2028 (IN $ MILLION)
FIGURE 25: ASIA PACIFIC PULMONARY DRUG DELIVERY MARKET, BY ACCESSORIES, 2019-2028 (IN $ MILLION)
FIGURE 26: ASIA PACIFIC PULMONARY DRUG DELIVERY MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
FIGURE 27: CHINA PULMONARY DRUG DELIVERY MARKET, 2019-2028 (IN $ MILLION)
FIGURE 28: JAPAN PULMONARY DRUG DELIVERY MARKET, 2019-2028 (IN $ MILLION)
FIGURE 29: INDIA PULMONARY DRUG DELIVERY MARKET, 2019-2028 (IN $ MILLION)
FIGURE 30: AUSTRALIA & NEW ZEALAND PULMONARY DRUG DELIVERY MARKET, 2019-2028 (IN $ MILLION)
FIGURE 31: SOUTH KOREA PULMONARY DRUG DELIVERY MARKET, 2019-2028 (IN $ MILLION)
FIGURE 32: THAILAND PULMONARY DRUG DELIVERY MARKET, 2019-2028 (IN $ MILLION)
FIGURE 33: INDONESIA PULMONARY DRUG DELIVERY MARKET, 2019-2028 (IN $ MILLION)
FIGURE 34: VIETNAM PULMONARY DRUG DELIVERY MARKET, 2019-2028 (IN $ MILLION)
FIGURE 35: REST OF ASIA PACIFIC PULMONARY DRUG DELIVERY MARKET, 2019-2028 (IN $ MILLION)
- GEOGRAPHICAL ANALYSIS
- ASIA PACIFIC
- CHINA
- JAPAN
- INDIA
- AUSTRALIA & NEW ZEALAND
- SOUTH KOREA
- THAILAND
- INDONESIA
- VIETNAM
- REST OF ASIA PACIFIC
- ASIA PACIFIC
- MARKET BY APPLICATION
- ASTHMA
- CHRONIC OBSTRUCTIVE PULMONARY DISEASE
- ALLERGIC RHINITIS
- CYSTIC FIBROSIS
- OTHER APPLICATIONS
- MARKET BY DISTRIBUTION CHANNEL
- HOSPITAL PHARMACIES
- RETAIL PHARMACIES
- E-COMMERCE
- MARKET BY END-USER
- HOSPITALS & CLINICS
- HOMECARE
- MARKET BY PRODUCT
- METERED DOSE INHALERS
- DRY POWDER INHALERS
- NEBULIZER
- PNEUMATIC NEBULIZER
- MESH NEBULIZER
- ULTRASONIC NEBULIZER
- ACCESSORIES
To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.